Skip to content
  • Sunday, 26 July 2026
  • 1:45 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Cellares and Papillon Therapeutics Partner to Automate Manufacturing of Investigational Therapy for Friedreich’s Ataxia
Pharmaceutical R&D

Cellares and Papillon Therapeutics Partner to Automate Manufacturing of Investigational Therapy for Friedreich’s Ataxia

Teuku Ryan Jul 23, 2026 0

In a significant development for the rare disease community, Cellares and Papillon Therapeutics have announced a strategic collaboration aimed at…

Read More
Pharmaceutical R&D

Cellares, TScan to assess automated manufacturing of TSC-101 therapy

Teuku Ryan Jun 4, 2026 0

In a significant development poised to accelerate the accessibility of cutting-edge cell therapies, Cellares and TScan Therapeutics have announced a…

Read More
Laboratory Automation & Robotics

Cellares Raises $257M Series D to Automate Cell Therapy Manufacturing

Lana Keisha Mar 24, 2026 0

The burgeoning field of cell and gene therapy, heralded as a revolutionary frontier in medicine, is currently grappling with a…

Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance directorYale Researchers Uncover Molecular Mechanism Preventing Fertilization Offering New Paths for Infertility Treatment and Contraceptive DevelopmentAre you still using housekeeping proteins for western blot normalization? It’s time for an upgrade.Breakthrough in Quantum State Measurement Opens New Frontiers for Multi-Photon Entangled Networks and Quantum Communication Technologies
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ